Participated · Series B · Aug 2021

MobileCoin builds privacy-protecting, near-instant payment infrastructure for phones, aiming to let users transact with greater anonymity than typical blockchains. The protocol uses a federated byzantine agreement rather than energy-intensive proof-of-work, which the company says reduces environmental impact. Signal integrated MobileCoin as a payments feature for UK users, and Mixin Messenger also supports MobileCoin transactions. Its token began trading in December and has appeared on exchanges including FTX, Bitfinex, BigOne and HotBit, with notable price volatility since. The company is four years old, based in San Francisco, has 40 employees and is hiring aggressively. MobileCoin recently added its first head of compliance and, separately, suffered the unexpected loss of its head of engineering. MobileCoin is a cryptocurrency designed for privacy-protecting, near-instant payments on mobile phones. Its protocol emphasizes private transactions and a wallet recovery feature the company says allows users to recover funds without entrusting a provider with private keys. The project received early technical guidance from Signal creator Moxie Marlinspike, and founders envisioned integrations with chat apps like Signal or WhatsApp. MobileCoin launched its token on the FTX exchange in early December. The MobileCoin Foundation has stated the project is not available to U.S. users or persons in other prohibited jurisdictions. The company also faces mobile-crypto risks (for example, loss of funds if a phone is compromised) and broader regulatory uncertainty that has challenged other messaging-app token projects. The team is led by founder Joshua Goldbard. MobileCoin is developing a fast, private, and easy-to-use cryptocurrency intended for deployment in resource-constrained mobile environments. The project emphasizes user privacy and aims to avoid third-party custody of keys while simplifying the user experience. MobileCoin plans integration with mobile messaging apps such as WhatsApp, Facebook Messenger, and Signal and published a whitepaper in December describing that vision. Transactions will synchronize to the network using the Stellar Consensus Protocol to achieve scalability and speed. The team includes advisors Moxie Marlinspike, Joshua Goldbard, and legal counsel Shane Glynn, and the project is actively recruiting engineers with experience building very large systems. MobileCoin is in very early stages, has initial funding, and faces regulatory and product-positioning challenges against mainstream payment services.

Participated · Seed · Nov 2018

Clearco offers non-dilutive financing tailored to ecommerce operators, supporting needs such as inventory, always-on marketing, major purchase orders and expansion across DTC, wholesale, retail, marketplaces and social commerce. The company provides qualifying brands access to up to $10 million with estimated terms of 4 to 12 months and states its offers include no personal guarantees and no all-asset liens. Clearco has delivered more than $3.3 billion in funding to over 11,000 businesses to date. In August 2026 it secured a $100 million asset-backed financing facility from Macquarie Group to expand its capacity to fund larger and longer-term commitments. Clearco's management, led by CEO Andrew Curtis, positions the business to support brands as they scale and diversify channels. The company markets its financing as flexible capital for inventory, marketing and growth initiatives.

Participated · Seed · Nov 2017

LabGenius develops next-generation therapeutic antibodies using its proprietary EVA™ discovery platform, which integrates machine learning, robotic automation and synthetic biology. The company operates a hybrid business model that pairs partnering with large biotech and pharmaceutical companies alongside a wholly-owned therapeutic pipeline. LabGenius plans to use the new funding to further develop its ML-driven drug discovery platform and to advance a pipeline of multispecific antibodies for the treatment of solid tumours toward the clinic. Led by CEO Dr. James Field, the company recently refreshed its board with appointees from new investors alongside existing directors. Financially, the Series B brings the company’s total funding to date to £58M. The company is based in London, UK. LabGenius is a London-headquartered machine learning-driven protein engineering company whose core technology is the EVA™ platform for rapid discovery of novel therapeutic antibodies. EVA has been used to co-optimize mono- and multi-specific single-domain antibodies for biochemical and biofunctional properties including stability, potency and selective tumor cell killing. The platform leverages predictive models to identify non-intuitive protein designs that perform well across multiple therapeutically valuable properties. LabGenius was awarded a competitive SMART grant from Innovate UK (part of a £25 million fund) to expand EVA's capabilities and accelerate optimization of antibody-based immune cell engager molecules. The funding will support R&D focused on lead optimization to improve selective cell killing profiles and reduce on-target, off-tumor effects. The company’s multidisciplinary team combines expertise in computer science, robotic automation and synthetic biology to advance computational technologies in R&D. LabGenius is a London-based biotech company that uses machine learning, robotic automation and synthetic biology to develop protein therapeutics. Its platform, EVA, is designed to rapidly identify and test potential new drugs by systematically searching billions of protein designs and experimentally validating those predicted to perform well. The approach aims to cut the cost and risk associated with drug development by integrating software and engineering into biology. The company notes that protein therapeutics represent roughly 30 percent of total pharmaceutical sales, underscoring the market opportunity. LabGenius recently closed a $15 million Series A extension, bringing the Series A to $25 million, providing capital to advance its platform. LabGenius develops a machine learning-driven, robotic platform called EVA that designs, conducts and learns from its own experiments to discover novel proteins. The company positions itself as a full-stack protein engineering operation that uses empirical computation engines to tackle hard protein-discovery problems. Its business model mixes partner-financed discovery programs (R&D payments, milestones and royalties) with an internal asset development effort. LabGenius runs commercial projects with pharma partners to move candidates to early preclinical stages; one ongoing collaboration is with Tillotts Pharma AG to discover IBD drug candidates. The startup intends to scale its team and expand the scope of its discovery platform using newly raised capital. LabGenius aims to evolve novel antibody fragments and build an integrated biopharmaceutical company powered by its protein engineering platform. LabGenius is a London-based synthetic biology startup that uses AI to evolve and engineer biological systems to create new materials. The company's core product is EVA, an autonomous AI-driven evolution engine designed to accelerate discovery and optimization of biological constructs. Following a $3.66M seed raise, LabGenius plans to establish an R&D facility in Central London to scale its lab operations. The seed round was jointly led by Kindred Capital and Acequia Capital, with participation from Backed VC, Beast Ventures, Berggruen Holdings, System.One, Charlie Songhurst and angel Tom McInerney. Foundational technology was co-developed by founder and CEO Dr. James Field and CSO Harry Rickerby, with prior funding from Innovate UK, BBSRC and SynbiCITE. The company has secured R&D contracts from the UK Ministry of Defence and several multinationals and is actively hiring to support growth.

Participated · Series A · Jun 2017

Mindstrong Health operates a digital care platform that uses smartphone-derived digital biomarkers and teletherapy to monitor and treat people with severe mental illnesses such as schizophrenia, bipolar disorder, obsessive-compulsive disorder and major depressive disorder. The company passively measures phone usage and keyboard-timing metrics to assess mental acuity and emotional valence; those measures are currently being validated in clinical trials. It provides access to therapists via phone, video and asynchronous text and positions its offering as a virtual hospital with complex care pathways for this population. Founder Paul Dagum has worked on these monitoring approaches since 2013 and remains the company’s chief scientific officer. Daniel Graf, an ex‑Uber executive, joined as CEO in November as Mindstrong moves from pure R&D toward commercial availability. The company frames the market need as large and costly to the U.S. healthcare system (roughly $20 billion per month) and says its platform could have broader applications across healthcare. Mindstrong Health develops measurement-science solutions and integrated health services designed to detect mental illness early and deliver preemptive care to improve outcomes. The company markets a diagnostic approach and care-delivery model aimed at modernizing mental health treatment. Mindstrong is led by Founder and CEO Paul Dagum and is based in Palo Alto, California. It is backed by a group of investors that includes ARCH Venture Partners, Foresite Capital, Bezos Expeditions, Decheng Capital, Berggruen Holdings, and One Mind Brain Health Impact Fund. Recently the company expanded its Series B financing with an additional $31 million investment. Board changes accompanying the financing include General Catalyst’s Hemant Taneja joining the board and Stephen K. Klasko joining as an independent director. Mindstrong Health develops measurement science that passively and continuously measures brain function through individuals' interactions with smartphones to detect cognitive and mood deterioration early. Its offerings include a patient-facing app, a provider-facing product, and clinical services delivered via a telehealth-enabled engagement and measurement platform. The company says its digital measures predict performance on gold-standard neurocognitive tests and is advancing clinical and translational research across brain health conditions globally. Mindstrong has partnered with pharmaceutical and clinical organizations, including Takeda Pharmaceutical Company Limited and Blackthorn Therapeutics, to apply its technology to identify digital biomarkers in conditions such as schizophrenia and treatment-resistant depression. The company announced a $15 million Series B and will use proceeds to scale the business and advance commercial deployments with partners across healthcare verticals. To date Mindstrong has raised $29 million following a $14 million Series A in June 2017. Mindstrong Health has developed patented science that transforms patterns of interaction on a smartphone into continuous, objective digital biomarkers of mood and cognition. The platform measures processing speed, attention, memory and executive function based on four years of clinical research. Mindstrong's products are in clinical trials with payers, providers, academics and the pharmaceutical industry. The company says its approach delivers real-time, high-resolution measures of brain function that could modernize assessment and intervention in behavioral health. Mindstrong was established in 2014 and is based in Palo Alto, California. In June 2017 it announced a $14 million Series A to support its technology and clinical operations expansion.

Participated · Series A · Mar 2017

eGenesis is a biotechnology company developing human-compatible engineered organs to address the global organ shortage. Its lead product candidate, the donor kidney EGEN-2784, carries three classes of genome edits: knockout of glycan-antigen synthesis genes, insertion of seven human transgenes to modulate rejection pathways, and inactivation of endogenous porcine retroviruses. The company’s EGEN genome engineering and production platform aims to comprehensively address cross-species molecular incompatibilities and viral risk. Proceeds from the $191 million Series D will be used to advance EGEN-2784 to a first-in-human kidney transplant study, advance pipeline programs (including acute liver failure and heart transplant), and scale production. In March 2024 eGenesis announced the world’s first successful porcine kidney transplant in a living patient under an FDA Expanded Access authorization, performed at Massachusetts General Hospital. The company says it is the only firm developing organs that carry all three classes of edits to address organ safety and efficacy. eGenesis develops human-compatible organs, tissues, and cells using gene-editing and genome-engineering to address barriers to xenotransplantation. The company harnesses gene editing technologies to make organs safe and effective for patients in need. Its development pipeline includes lead programs for kidney and islet cell transplants and earlier-stage programs targeting other solid organs. eGenesis intends to use its Series C proceeds to bring lead kidney and islet programs into human proof-of-concept studies, continue development of its proprietary gene-editing platform, and scale GMP production. The company is led by Paul Sekhri, President and Chief Executive Officer. Financially, eGenesis completed a $125m Series C financing in February 2021. eGenesis develops human-compatible organs using gene editing technologies such as CRISPR to overcome virology and immunology hurdles that have impeded xenotransplantation. The company is advancing an initial kidney product toward the clinic while pursuing programs in islet cell, liver, heart, and lung. It intends to use new funding to accelerate its kidney xenotransplant program into the clinic and to support advancement of other xenotransplant programs. eGenesis positions xenotransplantation as a potential solution for a broader organ recipient population and to expand applicability into areas such as cell therapy. The company is led by president and CEO Paul Sekhri and is based in Cambridge, Massachusetts. eGenesis completed a $100M Series B financing to support these efforts. eGenesis uses a CRISPR-based genome editing platform to engineer pig cells and organs intended for safe and effective human transplantation. The company’s core approach includes genomic engineering of pig cells, organ maturation, and eventual organ transplantation. eGenesis positions xenotransplantation as a solution to the severe shortage of transplantable human organs and aims to make it a routine lifesaving medical procedure. Its scientific team includes co-founder and CSO Luhan Yang and Harvard geneticist George Church, plus multiple scientists from Harvard with expertise in genome editing, synthetic biology, and transgenic animals. The company is in early stages of development and is advancing its platform toward delivering transplantable cells, tissues and organs. eGenesis announced a recent financing to support these development efforts.